370 related articles for article (PubMed ID: 25362568)
1. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
4. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
Mendes RE; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).
Pfaller MA; Sader HS; Castanheira M; Flamm RK; Mendes RE
J Antimicrob Chemother; 2018 Apr; 73(4):916-922. PubMed ID: 29294031
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
[TBL] [Abstract][Full Text] [Related]
7. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
8. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
9. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
J Glob Antimicrob Resist; 2017 Mar; 8():28-32. PubMed ID: 27939809
[TBL] [Abstract][Full Text] [Related]
12. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Pfaller MA; Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
[TBL] [Abstract][Full Text] [Related]
13. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
14. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
Mendes RE; Sader HS; Castanheira M; Flamm RK
J Chemother; 2018 Sep; 30(5):280-289. PubMed ID: 30843778
[TBL] [Abstract][Full Text] [Related]
15. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.
Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
J Antimicrob Chemother; 2016 Dec; 71(12):3453-3458. PubMed ID: 27609052
[TBL] [Abstract][Full Text] [Related]
17. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
